GSK Investigational Site

Shnghai 200126

0 studies enrolling now · 2 studies all time

What they study most

Neoplasms, Neoplasms, Head and Neck

Studies at this site

• Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1) — Completed
• Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma — Stopped early